Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
1998-05-08
2001-07-03
Spear, James M. (Department: 1615)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S489000, C424S046000, C424S423000, C424S434000, C424S449000, C424S435000, C424S450000, C514S825000, C514S826000, C514S879000, C514S903000, C514S937000
Reexamination Certificate
active
06254853
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to the field of pharmaceuticals. More specifically, this invention relates to pro-drugs of propofol that are water soluble and non-toxic.
Propofol (2,6-diisopropylphenol) is a low molecular weight phenol that is widely used as an intravenous sedative-hypnotic agent in the induction and maintenance of anesthesia or sedation in humans and animals. Among its advantages as an anesthetic are rapid onset of anesthesia, rapid clearance, and minimal side effects.
Propofol has a broad range of biological and medical applications. For example, it has been reported to be an anti-emetic (Castano et al.,
Rev. Esp. Anestesiol. Reanim
. 42(7):257-60 (1995)), an anti-epileptic (Kuisma M. et al.
Epilepsia
36(12):1241-1243 (1995)) and an anti-pruritic. (Borgeat, A. et al.,
Anesthesiology
80:642-56 (1994); Lawson, S. et al.,
Brit. J. Anesthesia
64:59-63 (1990).)
Propofol also has significant application as an antioxidant. (Sanchez et al., U.S. Pat. No. 5,308,874; Sanchez et al., U.S. Pat. No. 5,461,080; and Aarts L. et al.
FEBS Let
. 357(1):83-5 (1995).) In fact, it has been proposed that propofol can replace &agr;-tocopherol as antioxidant. (Aarts, supra.) Oxidative processes in living materials can result in significant damage. For example, oxidizing agents in the environment, such as smoke or ozone, are inhaled and cause oxidative stress to tissues of the respiratory system. Exposure to sunlight causes damage to skin as a result of chain reactions which originate when the ultraviolet light promotes the production of free radicals, such as superoxide and hydroxyl, within the tissue surface. Other forms of energetic radiation can have the same effect.
Propofol also has been shown to inhibit lipid peroxidation. (Misacchia et al., Pharmacol. Toxicol. (1991) 69:75-77.)
Oxidation also is a component of inflammation. For example, cyclooxygenase oxidizes arachidonic acid into prostaglandins which act as inflammatory mediators. Therefore, inhibiting oxidation is useful in the treatment of conditions with an inflammatory component. In addition, oxidative damage is also caused by other inflammation mediators such as tumor necrosis factor (TNF) and IL-1.
By inhibiting oxidation in tissues of the respiratory tract, propofol is useful in the prophylactic and therapeutic treatment of various pathologic respiratory conditions having an inflammatory component. These include, for example, acid aspiration, adult/infant respiratory distress syndrome, airway obstructive disease, asthma, bronchiolitis, bronchopulmonary dysplasia, cancer, chronic obstructive pulmonary disease (“COPD”), cystic fibrosis, emphysema, HIV-associated lung disease, idiopathic pulmonary fibrosis, immune-complex-mediated lung injury, exposure to an oxidizing agent, ischemia-reperfusion injury, mineral dust pneumoconiosis, drug-induced lung disease and silo-filler's disease.
There is an extensive accumulation of evidence that either the pathogenesis or the subsequent damage pathways in various neurodegenerative diseases involve reactive oxygen species, and are therefore amenable to treatment with antioxidants. (A review of this subject is given by Simonian A. and Coyle J. T., “Oxidative Stress in Neurodegenerative Diseases”, in
Ann. Rev. Pharmacol. Toxicol
. 36:83 (1996).) Examples of specific neurodegenerative diseases where oxidative damage may play a role include Friedrich's disease (Helveston et al.,
Clinical Neuropharnacology
19(3):271 (1996)), Parkinson's disease (Jenner,
Pathologie Biologie
44(1):57 (1996)), Alzheimer's disease (Good et al.,
Am. J. Pathol
. 149(1):21 (1996)), Huntington's disease (Borlongan et al.,
Journal of the Florida Medical Association
83(5):335 (1996)), amyotrophic lateral sclerosis (ALS) (Cudkowicz, M. et al. “Free-Radical Toxicity in Amyotrophic Lateral Sclerosis,” Ch. 16 in
Glutathione in the Nervous System
, Shaw, Ed. (1998); multiple sclerosis (MS) (Hooper, D. et al. “Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis,”
Proc. Natl. Acad. Sci. USA
95:675-680 (1998)); Pick disease (Castellani et al.,
Brain Research
696(1-2):268 (1995)) and aging itself (Beal,
Annals of Neurology
38(3):357 (1995).)
Similarly, the incidence of spinal cord injury in the United States is approximately 10,000 new cases per year. The human and financial costs of such injuries are devastating and therapies for treatment of these injuries are urgently needed. There is an accumulation of evidence that the pathogenesis of spinal cord injury, as well as injury to the brain, also involves reactive oxygen species and is therefore amenable to treatment with antioxidants (Castano et al., Rev.
Esp. Anestesiol. Reanim
. 42(7):257-60 (1995)). Alpha-tocopherol (vitamin E), a well known antioxidant, has been shown to decrease post-traumatic spinal cord ischemia and to enhance chronic neurological recovery. However, vitamin E is taken up into the central nervous system very slowly, making it an impractical agent for the treatment of acute neural injury.
A disadvantage to the use of propofol is that it is almost completely insoluble in water. Therefore, before it can be used for intravenous applications, such as anesthesia, it must be specially formulated in aqueous media using solubilizers or emulsifiers. The early developmental studies with intravenous propofol were performed with clear formulations containing the solubilizer Cremophor EL®. Later developmental studies and the current commercial products use an oil-in-water emulsion in which the emulsifier is the lecithin mixture Intralipid®. The commercial products are sold under various names including Diprivan®, Disoprofol®, Disoprivan®, and Rapinovet®.
Formulations that contain solubilizers or emulsifiers have been fraught with problems. Formulations containing the solubilizer Cremophor EL® have been reported to cause allergic complications (Briggs et al.,
Anesthesis
37:1099 (1982)). Stable emulsions are technically difficult to prepare and are consequently more expensive. Microbial growth has sometimes been observed in such emulsions and is believed to be supported by the emulsifier components (McHugh et al.,
Can. J. Anaesth
. 42(9):801-4 (1995)).
Other investigators have sought to overcome the problem of water insolubility by incorporating the propofol within a water-soluble carrier such as a cyclodextrin. Such a molecular complex allows delivery of propofol in a clear water solution and the eventual release of propofol in vivo. Unfortunately, the cyclodextrin complex produced cardiovascular complications in vivo, discouraging further study (Bielen et al.,
Anesth. Analg
. 82(5):920-4 (1996)).
Until now, there has been no pharmaceutical preparation of propofol formulated to deliver its beneficial effects without harmful side effects. Thus, the need exists for a water-soluble, stable, non-toxic pharmaceutical composition which is readily converted to propofol in vivo without the need for additives, solubilizers or emulsifiers.
SUMMARY OF THE INVENTION
This invention provides novel esters of propofol (2,6-diisopropylphenol) that are highly soluble in water and that metabolize rapidly into propofol. More specifically, this invention provides propofol hemisuccinate, propofol hemiglutarate, propofol hemiadipate, mono(propofol) phosphate, and di(propofol) phosphate. The esters of the present invention are at least one order of magnitude more soluble in water than propofol. The monophosphate and hemisuccinate esters are the most soluble.
The pro-drugs of this invention have little or no direct antioxidant activity, as a consequence of blockage of the phenolic group of the propofol molecule. In an in vivo environment, biological enzymes cause the hydrolysis of the pro-drugs, resulting in the release of free propofol, a potent antioxidant. Therefore the pro-drugs of this invention, when used in biological environments, possess all of the therapeutic applications that have been demonstrated for propofol.
These compositions offer advant
Hendler Sheldon S.
Sanchez Robert A.
Zielinski Jan
Howard S.
Spear James M.
Townsend and Townsend / and Crew LLP
Vyrex Corporation
LandOfFree
Water soluble pro-drugs of propofol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Water soluble pro-drugs of propofol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Water soluble pro-drugs of propofol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2509692